✦ LIBER ✦

Efficacy of N-acetylcysteine in Crohn's disease — An open label pilot study

✍ Scribed by Ramzan, Nizar N.; Leighton, Jonathan L.; Heigh, Russell I.; Moriarty, Cheryl; Cangemi, John R.

Book ID: 124144060
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 173 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)81389-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

N-Acetylcysteine (NAC) in Young Marijuan

N-Acetylcysteine (NAC) in Young Marijuana Users: An Open-Label Pilot Study

✍ Kevin M. Gray; Noreen L. Watson; Matthew J. Carpenter; Steven D. LaRowe 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 76 KB

An open-label pilot study of low-dose th

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

✍ Eric A. Vasiliauskas; Lori Y. Kam; Maria T. Abreu-Martin; Philip V. Hassard; Kos 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 175 KB

An open-label trial of N-acetylcysteine

An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study

✍ Pascale N. Mardikian; Steven D. LaRowe; Sarra Hedden; Peter W. Kalivas; Robert J 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Extracorporeal photopheresis for the tre

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study

✍ Maria T. Abreu; Christian von Tirpitz; Robert Hardi; Martin Kaatz; Gert Van Assc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

## Background: Extracorporeal photopheresis (ecp) is effective in immune-mediated disorders. a prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ecp in patients with active crohn's disease (cd) who were refractory to or intolerant of immunosuppressants and/o

Adalimumab in patients with Crohn’s dise

Adalimumab in patients with Crohn’s disease – safety and efficacy in an open-label single centre study

✍ J. SEIDERER; S. BRAND; J. DAMBACHER; S. PFENNIG; M. JÜRGENS; B. GÖKE; T. OCHSENK 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 538 KB

CQP 201-403 in Parkinson's disease: An o

CQP 201-403 in Parkinson's disease: An open-label pilot study

✍ Dr. Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over a n average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in suffici